XTX Topco Ltd Increases Stock Holdings in Koninklijke Philips N.V. $PHG

XTX Topco Ltd increased its holdings in shares of Koninklijke Philips N.V. (NYSE:PHG) by 207.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 29,421 shares of the technology company’s stock after purchasing an additional 19,840 shares during the quarter. XTX Topco Ltd’s holdings in Koninklijke Philips were worth $706,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AlphaCore Capital LLC purchased a new position in shares of Koninklijke Philips during the 2nd quarter worth about $41,000. Whipplewood Advisors LLC grew its holdings in Koninklijke Philips by 39.1% in the second quarter. Whipplewood Advisors LLC now owns 2,108 shares of the technology company’s stock valued at $51,000 after purchasing an additional 592 shares during the period. MAI Capital Management increased its position in Koninklijke Philips by 167.7% during the second quarter. MAI Capital Management now owns 2,380 shares of the technology company’s stock worth $57,000 after purchasing an additional 1,491 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in Koninklijke Philips by 1,170.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 2,439 shares of the technology company’s stock worth $62,000 after purchasing an additional 2,247 shares during the period. Finally, Blue Trust Inc. raised its stake in Koninklijke Philips by 30.0% during the second quarter. Blue Trust Inc. now owns 4,408 shares of the technology company’s stock worth $106,000 after purchasing an additional 1,017 shares during the period. Hedge funds and other institutional investors own 13.67% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PHG. Weiss Ratings reissued a “hold (c-)” rating on shares of Koninklijke Philips in a research note on Monday. Wall Street Zen upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Koninklijke Philips presently has an average rating of “Buy”.

Koninklijke Philips Trading Down 0.4%

NYSE:PHG opened at $28.22 on Wednesday. The business’s 50-day moving average is $27.92 and its two-hundred day moving average is $26.30. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.32 and a quick ratio of 0.86. Koninklijke Philips N.V. has a 12 month low of $21.48 and a 12 month high of $29.54. The firm has a market capitalization of $27.17 billion, a PE ratio of 141.08, a price-to-earnings-growth ratio of 0.76 and a beta of 0.79.

Koninklijke Philips (NYSE:PHG) last issued its earnings results on Tuesday, November 4th. The technology company reported $0.37 earnings per share for the quarter, hitting the consensus estimate of $0.37. Koninklijke Philips had a return on equity of 12.14% and a net margin of 1.07%.The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $4.30 billion. Research analysts predict that Koninklijke Philips N.V. will post 1.63 earnings per share for the current fiscal year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.